Hospital & Healthcare Services · Founded 2004 · www.shalby.org · BSE 540797 · NSE SHALBY · ISIN INE597J01018
No Notes Added Yet
Business
Shalby Ltd. is a leading multi-specialty hospital chain based in India. The company operates a network of hospitals primarily offering tertiary and quaternary healthcare services. Its core business model revolves around providing comprehensive medical care, including advanced surgical procedures, medical consultations, diagnostics, and emergency services. Shalby is particularly renowned for its orthopedic services, especially joint replacement surgeries (knee, hip, shoulder), and it has a strong focus on high-end tertiary care. The company makes money through patient charges for medical services, procedures, room occupancy, diagnostics, pharmacy sales, and international patient services.
Revenue Mix
Shalby Ltd. primarily operates within a single business segment: Hospital & Healthcare Services. While specific percentage breakdowns of revenue by medical specialty are not publicly disaggregated consistently, a significant portion of its revenue is historically derived from orthopedics, particularly joint replacement surgeries. Other key specialties contributing to revenue include cardiology, neurology, oncology, renal sciences, and critical care. Revenue is generated from a mix of domestic and international patients, with a strong emphasis on inpatient surgical procedures.
Industry
The Indian hospital industry is fragmented but witnessing consolidation, with both large corporate chains and standalone hospitals. It is characterized by increasing demand driven by population growth, rising disposable incomes, lifestyle diseases, and improving insurance penetration. Shalby Ltd. is positioned as a mid-sized to large multi-specialty hospital chain with a strong brand recall in orthopedics, particularly joint replacements. It competes with larger chains like Apollo Hospitals, Fortis Healthcare, Max Healthcare, and smaller regional players. Shalby has a significant presence in Western and Central India (Gujarat, Rajasthan, MP) and aims for a pan-India footprint. Its focus on specialized, high-acuity care differentiates it from general practitioners and primary care centers.
MOAT
Shalby's primary competitive advantage stems from its specialized expertise and reputation in orthopedics, particularly joint replacement surgeries, often associated with its founder, Dr. Vikram Shah. This specialization has built a strong brand equity and patient trust in this niche. The company also benefits from:
Scale in Specialty: High volume of joint replacement surgeries contributes to surgeon expertise and operational efficiency.
Doctor-led Model: Strong relationships with experienced doctors, particularly in its core specialties.
Regional Dominance: Established presence and brand in key regions like Gujarat.
However, the overall healthcare industry faces high competition, and while Shalby has a niche, it generally operates in a highly competitive market where switching costs for general healthcare services can be moderate.
Growth Drivers
Increasing Healthcare Expenditure: Rising income levels, greater health awareness, and increased health insurance penetration are boosting demand for quality healthcare.
Medical Tourism: India's cost-effectiveness and quality of care attract international patients, especially for complex surgeries like joint replacements.
Expansion & Bed Capacity Addition: The company's strategy includes organic expansion (adding beds in existing hospitals) and inorganic growth (acquisitions, tie-ups, management contracts) to expand its geographical reach.
Focus on High-Demand Specialties: Continued emphasis on orthopedic, cardiac, oncology, and other tertiary care services which have high growth potential.
Aging Population & Lifestyle Diseases: An aging population and increasing prevalence of chronic and lifestyle-related diseases drive demand for specialized medical interventions.
Risks
Intense Competition: Highly competitive landscape from existing large hospital chains, regional players, and new entrants.
Regulatory Risks: Government interventions like price caps on medical procedures (e.g., knee implants), drug pricing controls, and evolving healthcare policies can impact profitability.
Doctor & Staff Retention: Reliance on skilled medical professionals makes recruitment and retention a critical challenge and cost factor.
Capital Intensive Business: Hospital expansion and technology upgrades require significant capital expenditure, potentially impacting financial leverage.
Operational Challenges: Managing a large network of hospitals effectively, maintaining quality standards, and controlling operating costs are ongoing challenges.
Pandemic-Related Disruptions: Future health crises could lead to deferral of elective surgeries and impact patient footfalls.
Management & Ownership
Shalby Ltd. was founded by Dr. Vikram Shah, a renowned joint replacement surgeon, who serves as the Chairman and Managing Director. The company is promoter-led, with Dr. Shah and his family holding a significant stake, reflecting a strong vested interest in the company's performance. The management team comprises experienced professionals from the healthcare and finance sectors. The promoter group's substantial ownership demonstrates commitment and long-term vision. Institutional and public shareholders form the remainder of the ownership structure.
Outlook
Shalby Ltd. is well-positioned to benefit from the growing Indian healthcare market, particularly with its established brand in orthopedics and expansion plans. The increasing demand for quality healthcare, driven by demographics and rising affluence, provides a strong tailwind. The company's strategy of expanding its hospital network through a mix of owned, leased, and managed assets, coupled with a focus on high-acuity specialties, offers potential for sustained revenue and profitability growth. However, the outlook is tempered by intense competition, the capital-intensive nature of the hospital business, and potential regulatory pressures on pricing. Efficient execution of expansion plans, effective cost management, and diversification beyond its core orthopedic strength will be crucial for long-term success, while balancing the risks posed by a competitive and evolving regulatory environment.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 244 | 279 | 268 | 276 | 265 | 296 | 285 | 272 | 287 | 331 |
| Other Income | 5 | 10 | 7 | 5 | 5 | 7 | 4 | 7 | 8 | 7 |
| Total Income | 249 | 289 | 275 | 281 | 270 | 303 | 290 | 279 | 296 | 339 |
| Total Expenditure | 205 | 234 | 235 | 242 | 244 | 255 | 244 | 242 | 258 | 290 |
| Operating Profit | 44 | 55 | 40 | 39 | 26 | 49 | 46 | 37 | 37 | 49 |
| Interest | 6 | 8 | 9 | 11 | 11 | 9 | 10 | 11 | 9 | 11 |
| Depreciation | 16 | 16 | 17 | 16 | 16 | 17 | 17 | 18 | 18 | 19 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 22 | 30 | 14 | 12 | -1 | 23 | 19 | 9 | 10 | 20 |
| Provision for Tax | 6 | 16 | 11 | 15 | 11 | 15 | 12 | 8 | -9 | 9 |
| Profit After Tax | 16 | 15 | 2 | -3 | -12 | 8 | 7 | 1 | 18 | 10 |
| Adjustments | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | -0 | 0 |
| Profit After Adjustments | 17 | 16 | 3 | -2 | -11 | 9 | 8 | 2 | 18 | 11 |
| Adjusted Earnings Per Share | 1.5 | 1.5 | 0.3 | -0.2 | -1 | 0.8 | 0.8 | 0.2 | 1.7 | 1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 290 | 324 | 378 | 462 | 487 | 431 | 699 | 805 | 934 | 1087 | 1141 | 1175 |
| Other Income | 2 | 7 | 10 | 9 | 17 | 9 | 12 | 23 | 19 | 28 | 27 | 26 |
| Total Income | 293 | 331 | 388 | 472 | 504 | 440 | 711 | 827 | 953 | 1115 | 1168 | 1204 |
| Total Expenditure | 235 | 252 | 299 | 379 | 404 | 344 | 577 | 667 | 755 | 952 | 996 | 1034 |
| Operating Profit | 58 | 78 | 89 | 93 | 100 | 96 | 134 | 161 | 198 | 162 | 172 | 169 |
| Interest | 10 | 11 | 12 | 9 | 7 | 5 | 8 | 11 | 18 | 41 | 41 | 41 |
| Depreciation | 11 | 17 | 23 | 33 | 36 | 37 | 43 | 48 | 52 | 66 | 70 | 72 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 36 | 50 | 54 | 50 | 57 | 55 | 79 | 102 | 128 | 56 | 61 | 58 |
| Provision for Tax | -0 | 22 | 15 | 19 | 29 | 13 | 25 | 34 | 45 | 54 | 26 | 20 |
| Profit After Tax | 36 | 29 | 39 | 32 | 28 | 42 | 54 | 68 | 83 | 2 | 35 | 36 |
| Adjustments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 1 |
| Profit After Adjustments | 38 | 30 | 39 | 32 | 28 | 42 | 54 | 68 | 84 | 6 | 37 | 39 |
| Adjusted Earnings Per Share | 0 | 0 | 3.6 | 2.9 | 2.6 | 3.9 | 5 | 6.3 | 7.8 | 0.6 | 3.5 | 3.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | 12% | 21% | 15% |
| Operating Profit CAGR | 6% | 2% | 12% | 11% |
| PAT CAGR | 1650% | -20% | -4% | -0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -50% | -17% | -5% | NA% |
| ROE Average | 3% | 4% | 5% | 7% |
| ROCE Average | 7% | 9% | 9% | 9% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 205 | 251 | 751 | 780 | 799 | 835 | 876 | 928 | 1000 | 992 | 1005 |
| Minority's Interest | 0 | -1 | 0 | 0 | 0 | 0 | -0 | -0 | 7 | 3 | 0 |
| Borrowings | 201 | 285 | 75 | 57 | 49 | 36 | 87 | 67 | 176 | 137 | 153 |
| Other Non-Current Liabilities | 6 | 5 | 65 | 73 | 96 | 115 | 146 | 202 | 212 | 153 | 168 |
| Total Current Liabilities | 92 | 199 | 138 | 88 | 83 | 82 | 172 | 194 | 323 | 455 | 576 |
| Total Liabilities | 504 | 741 | 1030 | 998 | 1027 | 1066 | 1282 | 1391 | 1719 | 1740 | 1902 |
| Fixed Assets | 319 | 323 | 650 | 692 | 672 | 660 | 675 | 685 | 966 | 955 | 1046 |
| Other Non-Current Assets | 120 | 259 | 144 | 109 | 121 | 136 | 158 | 189 | 200 | 127 | 137 |
| Total Current Assets | 64 | 159 | 236 | 197 | 234 | 271 | 442 | 517 | 552 | 658 | 719 |
| Total Assets | 504 | 741 | 1030 | 998 | 1027 | 1066 | 1282 | 1391 | 1719 | 1740 | 1902 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 27 | 9 | 12 | 12 | 5 | 8 | 6 | 56 | 12 | 27 | 35 |
| Cash Flow from Operating Activities | 5 | 60 | 14 | 43 | 55 | 79 | 19 | 68 | 20 | -4 | -0 |
| Cash Flow from Investing Activities | -98 | -153 | -237 | 1 | -31 | -51 | -60 | -61 | 38 | -36 | -97 |
| Cash Flow from Financing Activities | 75 | 96 | 222 | -51 | -21 | -30 | 90 | -50 | -151 | 48 | 84 |
| Net Cash Inflow / Outflow | -19 | 3 | -0 | -6 | 3 | -2 | 49 | -43 | -93 | 8 | -13 |
| Closing Cash & Cash Equivalent | 9 | 12 | 12 | 5 | 8 | 6 | 56 | 12 | 27 | 35 | 22 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 3.65 | 2.93 | 2.55 | 3.93 | 5.01 | 6.31 | 7.83 | 0.58 | 3.48 |
| CEPS(Rs) | 5.45 | 5.19 | 5.74 | 6 | 5.89 | 7.33 | 8.97 | 10.79 | 12.64 | 6.3 | 9.74 |
| DPS(Rs) | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1.2 | 1.2 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 0 | 69.57 | 72.2 | 74 | 77.28 | 81.13 | 86.37 | 93.06 | 92.2 | 93.38 |
| Core EBITDA Margin(%) | 19.13 | 22.08 | 20.88 | 18.06 | 17 | 20.27 | 17.39 | 17.17 | 19.13 | 12.4 | 12.71 |
| EBIT Margin(%) | 15.97 | 19.01 | 17.49 | 12.89 | 13.17 | 13.83 | 12.4 | 13.99 | 15.62 | 8.88 | 8.93 |
| Pre Tax Margin(%) | 12.37 | 15.6 | 14.21 | 10.9 | 11.65 | 12.78 | 11.32 | 12.68 | 13.73 | 5.13 | 5.31 |
| PAT Margin (%) | 12.51 | 8.87 | 10.36 | 6.85 | 5.67 | 9.83 | 7.72 | 8.41 | 8.94 | 0.18 | 3.04 |
| Cash Profit Margin (%) | 16.41 | 14.02 | 16.41 | 14.02 | 13.06 | 18.37 | 13.86 | 14.38 | 14.54 | 6.23 | 9.17 |
| ROA(%) | 8.49 | 4.61 | 4.42 | 3.12 | 2.72 | 4.05 | 4.6 | 5.06 | 5.37 | 0.11 | 1.9 |
| ROE(%) | 19.5 | 12.6 | 7.81 | 4.13 | 3.49 | 5.19 | 6.31 | 7.51 | 8.67 | 0.19 | 3.48 |
| ROCE(%) | 13.34 | 12.21 | 9.15 | 6.94 | 7.49 | 6.85 | 9.08 | 10.72 | 12.23 | 7.07 | 6.88 |
| Receivable days | 33.29 | 36.67 | 40.8 | 52.21 | 66.06 | 80.28 | 51.09 | 47.01 | 49.06 | 53.7 | 64.54 |
| Inventory Days | 8.37 | 8.53 | 9.51 | 9.82 | 10.51 | 16.21 | 37.64 | 69.5 | 82.21 | 93.09 | 111.22 |
| Payable days | 4430.53 | 433.29 | 415.03 | 489.09 | 401.5 | 619.39 | 761.23 | 492.96 | 624.41 | 394.9 | 297.82 |
| PER(x) | 0 | 0 | 56.05 | 44.09 | 18.13 | 25.69 | 23.31 | 21.33 | 30.57 | 342.2 | 36.48 |
| Price/Book(x) | 0 | 0 | 2.94 | 1.79 | 0.63 | 1.31 | 1.44 | 1.56 | 2.57 | 2.15 | 1.36 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.39 | 1.08 | 0.99 | 0.86 | 0.89 | 0.5 | 0 | 0 |
| EV/Net Sales(x) | 1.02 | 1.23 | 5.83 | 3.12 | 1.1 | 2.44 | 1.87 | 1.96 | 3.06 | 2.32 | 1.65 |
| EV/Core EBITDA(x) | 5.12 | 5.11 | 24.79 | 15.54 | 5.33 | 10.89 | 9.75 | 9.79 | 14.43 | 15.53 | 10.95 |
| Net Sales Growth(%) | 5.44 | 11.49 | 16.75 | 22.29 | 5.32 | -11.49 | 62.21 | 15.16 | 16.01 | 16.41 | 5.01 |
| EBIT Growth(%) | -4.43 | 32.68 | 7.41 | -9.88 | 7.68 | -7.08 | 45.45 | 29.91 | 29.48 | -33.77 | 5.51 |
| PAT Growth(%) | 47.93 | -20.97 | 36.47 | -19.19 | -12.85 | 53.56 | 27.4 | 25.4 | 23.38 | -97.7 | 1706.46 |
| EPS Growth(%) | 0 | 0 | 0 | -19.6 | -12.86 | 53.67 | 27.66 | 25.9 | 24.07 | -92.6 | 500.66 |
| Debt/Equity(x) | 1.09 | 1.31 | 0.15 | 0.09 | 0.08 | 0.05 | 0.18 | 0.15 | 0.31 | 0.43 | 0.54 |
| Current Ratio(x) | 0.7 | 0.8 | 1.7 | 2.23 | 2.81 | 3.32 | 2.56 | 2.66 | 1.71 | 1.45 | 1.25 |
| Quick Ratio(x) | 0.62 | 0.76 | 1.62 | 2.09 | 2.62 | 3.03 | 1.86 | 1.71 | 0.98 | 0.74 | 0.6 |
| Interest Cover(x) | 4.44 | 5.58 | 5.34 | 6.49 | 8.66 | 13.13 | 11.51 | 10.66 | 8.28 | 2.36 | 2.47 |
| Total Debt/Mcap(x) | 0 | 0 | 0.05 | 0.05 | 0.12 | 0.04 | 0.12 | 0.1 | 0.12 | 0.2 | 0.39 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.24 | 74.25 | 74.25 | 74.27 | 74.27 | 74.27 | 74.33 | 74.33 | 74.33 | 74.33 |
| FII | 4.88 | 5.35 | 5.37 | 4.65 | 4.54 | 5.2 | 4.64 | 4.47 | 4.36 | 4.46 |
| DII | 0 | 0.06 | 0.09 | 0.14 | 0.18 | 0.2 | 0.2 | 0.2 | 0.25 | 0.3 |
| Public | 20.89 | 20.35 | 20.29 | 20.94 | 21.01 | 20.33 | 20.84 | 21.01 | 21.07 | 20.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.03 | 8.03 | 8.03 | 8.03 |
| FII | 0.53 | 0.58 | 0.58 | 0.5 | 0.49 | 0.56 | 0.5 | 0.48 | 0.47 | 0.48 |
| DII | 0 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Public | 2.26 | 2.2 | 2.19 | 2.26 | 2.27 | 2.2 | 2.25 | 2.27 | 2.28 | 2.26 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +5% | +12% | +21% | +15% |
| Operating Profit CAGR | +6% | +2% | +12% | +11% |
| PAT CAGR | +1650% | -20% | -4% | 0% |
| Share Price CAGR | -50% | -17% | -5% | — |
| ROE Average | +3% | +4% | +5% | +7% |
| ROCE Average | +7% | +9% | +9% | +9% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.24 | 74.25 | 74.25 | 74.27 | 74.27 | 74.27 | 74.33 | 74.33 | 74.33 | 74.33 |
| FII | 4.88 | 5.35 | 5.37 | 4.65 | 4.54 | 5.2 | 4.64 | 4.47 | 4.36 | 4.46 |
| DII | 0 | 0.06 | 0.09 | 0.14 | 0.18 | 0.2 | 0.2 | 0.2 | 0.25 | 0.3 |
| Public | 20.89 | 20.35 | 20.29 | 20.94 | 21.01 | 20.33 | 20.84 | 21.01 | 21.07 | 20.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.03 | 8.03 | 8.03 | 8.03 |
| FII | 0.53 | 0.58 | 0.58 | 0.5 | 0.49 | 0.56 | 0.5 | 0.48 | 0.47 | 0.48 |
| DII | 0 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Public | 2.26 | 2.2 | 2.19 | 2.26 | 2.27 | 2.2 | 2.25 | 2.27 | 2.28 | 2.26 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.